
Catalog: #2291

Store at: -20ºC

For Research Use Only. Not For Use In Diagnostic Procedures.


Applications Flow Cytometry	Detection Anti-Rabbit IgG	Clonality Monoclonal	lsotype Rabbit IgGk			
Format:	Unconjugated					
Cross Reactivity:	Predicted to work with mouse, rat and other homologues.					
Formulation:	1X PBS, 0.02% NaN3, 50% Glycerol, 0.1% BSA					
Preparation:	Protein A+G					
Reactivity:	Human					
Recommended Usage:	1μ g/mL – 0.001 μ g/mL. It is recommended that the reagent be titrated for optimal performance for each application. See product image legends for additional information.					
Immunogen:	A synthetic phospho-peptide corre human phospho BLNK	sponding to residues surro	ounding Tyr84 of			
Description:	BLNK protein, known as SLP-65 pla lineage cells. BLNK associates with membrane through its N-terminal I its tyrosine, BLNK binds to Btk, Vax associations, BLNK mediates Ca2+ kinase activation. After phosphoryl their SH2 domains and mediates P signaling molecules such as Vav, G role in BCR-dependent progression survival, activation, proliferation, a	proteins in the cytoplasm leucine zipper motif. Upon v, Brb2, Syk, and HPK1. The mobilization, for ERK1/2, lation, BLNK binds Btk and LC γ 2 activation by Btk. BL Grb2, Syk, and HPK1. BLNK of B cell development, BC	ic side of plasma BLNK activation on prough this JNK and p38 MAP I PLCγ2 through NK also binds other C plays aa important CR-mediated B cell			
References:	Fu, C., et al. (1998) Immunity 9: 93 Goitsuka, R., et al. (1998) J. Immur Tsuji, S., et al. (2001) J. Exp. Med. 3	nol. 161: 5804–5808.				






lgG	Treatment	Peptide Block	Median : BL1-A
H4	IFNa	Non-phos	88579
H4	Ctrl	Non-phos	2748
H4	IFNa	Phos	700
H4	Ctrl	Phos	343
H4	IFNa	-	75009
H4	Ctrl	-	4167
2' only	Ctrl	-	352

Peptide blocking flow cytometric analysis of Daudi cells secondary antibody only negative control (light blue) or untreated (red) or with $IFN\alpha + IL-4 + pervanadate$ (green) or untreated and blocked with phospho-peptide (black) or treated and blocked with phospho peptide (gold) or untreated and blocked with non-phospho peptide (dark blue) or treated and blocked with non-phospho peptide (purple) using Phospho-BLNK (Tyr84) antibody BLNKY84-H4 at 0.01 µg/mL. Cat. #2291.



Flow cytometric analysis of Daudi cells secondary antibody only negative control (blue) or untreated (red) or treated with IFN α + IL-4 + pervanadate (green) using Phospho-BLNK (Tyr84) antibody BLNKY84-H4 at 0.01 µg/mL. Cat. #2291.





Flow cytometric analysis of Daudi cells secondary antibody only negative control (blue) or untreated (red) or treated with IFNa + IL-4 + pervanadate (green) using 10 ng/mL of Phospho-BLNK (Tyr84) antibody BLNKY84-H4 (Abwiz Cat. #2291) or Company B antibody at 2.5 ug/mL (manufacturer's recommended concentration).

